Takeaway

• In elderly patients with newly diagnosed mantle cell lymphoma (MCL), the addition of ibrutinib to standard-of-care chemoimmunotherapy (bendamustine-rituximab, BR) and rituximab maintenance significantly improved progression free survival (PFS).

Why this matters

• MCL is often diagnosed in people aged 65 years or over.
• Outcomes of MCL are greatly unsatisfactory...